Biocompatible Red Blood Membrane-Carbon Dot Hybrids for Near-Infrared Imaging-Guided Chemotherapy
Source abstract
Abstract
The hydrophobicity has been known as a pivotal factor limiting the therapeutic capacity of cancer drugs. Biocompatible nanocarriers as a potential platform for drug delivery can increase the solubility of hydrophobic drugs and prolong drug half-life, therefore improving therapeutic efficacies. Herein, we use the treated red blood cell membrane (RBM) as a nanocarrier to delivery hydrophobic carbon dot and paclitaxel (RBM-CD–PTX) for imaging-guided chemotherapy. The CD in RBM-CD with good biosafety endows them with excellent optical properties for fluorescent imaging from visible light to near-infrared light in cellular and animal models. The RBM-CD exhibited a high PTX loading capacity (loading capacity, 30.23%). The RBM-CD–PTX can be easily delivered and efficiently accumulated in tumor tissues, releasing PTX molecules to inhibit tumor growth. Such a nanoplatform manifests great potential to deliver clinical reagents for imaging-guided cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Carbon and Quantum Dots Applications · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pathology and Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230601, P. R. China
High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China
University of Science and Technology of China, Hefei, Anhui 230026, P. R. China
Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P. R. China
Funding
National Key Research and Development Program of China · Hefei Institutes of Physical Science, Chinese Academy of Sciences · National Natural Science Foundation of China · High Magnetic Field Laboratory of Anhui Province · Hefei Municipal Natural Science Foundation
References (51)
Show source-provided references
1. 10.3322/caac.2173110.3322/caac.21731 ↗
2. 10.1158/2159-8290.cd-20-131210.1158/2159-8290.cd-20-1312 ↗
3. 10.7150/thno.5782810.7150/thno.57828 ↗
4. 10.1016/s0140-6736(21)00797-210.1016/s0140-6736(21)00797-2 ↗
5. 10.3322/caac.2165710.3322/caac.21657 ↗
6. 10.1038/s41467-021-23466-510.1038/s41467-021-23466-5 ↗
7. 10.1038/s41467-020-19933-010.1038/s41467-020-19933-0 ↗
8. 10.1016/j.colsurfb.2019.04.05010.1016/j.colsurfb.2019.04.050 ↗
9. 10.1158/0008-5472.can-13-278710.1158/0008-5472.can-13-2787 ↗
10. 10.1158/0008-5472.can-12-456110.1158/0008-5472.can-12-4561 ↗
11. 10.1002/anie.20190835710.1002/anie.201908357 ↗
12. 10.1039/c9cs00807a10.1039/c9cs00807a ↗
13. 10.1002/adma.20200145710.1002/adma.202001457 ↗
14. 10.1002/advs.20180162910.1002/advs.201801629 ↗
15. 10.1039/c9tc06406k10.1039/c9tc06406k ↗
16. 10.1016/j.trac.2020.11600810.1016/j.trac.2020.116008 ↗
17. 10.1039/c9cs00166b10.1039/c9cs00166b ↗
18. 10.1021/acs.accounts.9b0030510.1021/acs.accounts.9b00305 ↗
19. 10.1039/c8sc03510e10.1039/c8sc03510e ↗
20. 10.1016/j.trac.2021.11622210.1016/j.trac.2021.116222 ↗
21. 10.1016/j.apsb.2021.09.03010.1016/j.apsb.2021.09.030 ↗
22. 10.1038/s41467-022-29082-110.1038/s41467-022-29082-1 ↗
23. 10.1038/s41467-022-32975-w10.1038/s41467-022-32975-w ↗
24. 10.1016/j.msec.2020.11149810.1016/j.msec.2020.111498 ↗
25. 10.1016/j.snb.2018.05.07910.1016/j.snb.2018.05.079 ↗
26. 10.1002/adma.20150130610.1002/adma.201501306 ↗
27. 10.1002/adhm.20170081810.1002/adhm.201700818 ↗
28. 10.2147/ijn.s6886110.2147/ijn.s68861 ↗
29. 10.1021/acs.chemrev.5b0004610.1021/acs.chemrev.5b00046 ↗
30. 10.1016/j.addr.2021.11399210.1016/j.addr.2021.113992 ↗
31. 10.1021/acsami.2c0094110.1021/acsami.2c00941 ↗
32. 10.1016/j.carbon.2021.11.05210.1016/j.carbon.2021.11.052 ↗
33. 10.1021/acsami.0c0699610.1021/acsami.0c06996 ↗
34. 10.3390/pharmaceutics1101001010.3390/pharmaceutics11010010 ↗
35. 10.1016/j.addr.2008.03.01410.1016/j.addr.2008.03.014 ↗
36. 10.1002/anie.20220687010.1002/anie.202206870 ↗
37. 10.1007/s10534-021-00338-510.1007/s10534-021-00338-5 ↗
38. 10.1021/acsami.0c1712110.1021/acsami.0c17121 ↗
39. 10.3390/pharmaceutics1303036810.3390/pharmaceutics13030368 ↗
40. 10.1002/adhm.20120013810.1002/adhm.201200138 ↗
41. 10.1021/acsami.1c0413410.1021/acsami.1c04134 ↗
42. 10.1080/10717544.2022.209449810.1080/10717544.2022.2094498 ↗
43. 10.1016/j.bbrc.2017.05.04210.1016/j.bbrc.2017.05.042 ↗
44. 10.1021/acs.langmuir.3c0007510.1021/acs.langmuir.3c00075 ↗
45. 10.1021/acsnano.0c0514310.1021/acsnano.0c05143 ↗
46. 10.1016/j.jconrel.2018.09.02210.1016/j.jconrel.2018.09.022 ↗
47. 10.1038/s41467-019-09830-610.1038/s41467-019-09830-6 ↗
48. 10.1016/j.biomaterials.2015.02.08710.1016/j.biomaterials.2015.02.087 ↗
49. 10.1088/2631-7990/ac8e3a10.1088/2631-7990/ac8e3a ↗
50. 10.1002/smll.20160226310.1002/smll.201602263 ↗
51. 10.1002/adfm.20150152410.1002/adfm.201501524 ↗